FY2026 EPS Estimates for OPKO Health Raised by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate for OPKO Health to a loss of $0.18 per share from a projected loss of $0.23, maintaining a Buy rating.
• OPKO reported a quarterly loss of $0.07 per share, matching consensus, while revenue of $130.83 million fell short of analyst estimates and was down 56.9% year over year.
• Analyst sentiment is broadly positive, with MarketBeat reporting a Moderate Buy consensus and a $3.42 average price target. OPKO also agreed to sell most of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for shares of OPKO Health in a report released on Thursday, November 5th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.18) per share for the year, up from their previous forecast of ($0.23). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OPKO Health's Q4 2026 earnings at ($0.11) EPS, Q1 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.27) EPS.

A number of other research analysts have also weighed in on OPK. Zacks Research raised shares of OPKO Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 28th. Barrington Research upgraded OPKO Health from a "market perform" rating to an "outperform" rating and set a $2.25 price objective for the company in a research note on Friday, October 16th. UBS Group set a $4.00 target price on OPKO Health in a report on Friday, October 16th. Piper Sandler reaffirmed an "overweight" rating and issued a $4.00 price target (up from $3.00) on shares of OPKO Health in a research note on Friday, October 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $3.42.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.73 on Monday. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -9.11 and a beta of 1.52. The company's 50-day simple moving average is $1.59 and its 200-day simple moving average is $1.36. The company has a quick ratio of 4.65, a current ratio of 4.97 and a debt-to-equity ratio of 0.41. OPKO Health has a 52-week low of $0.98 and a 52-week high of $1.86.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $130.83 million during the quarter, compared to analyst estimates of $136.62 million. OPKO Health had a negative net margin of 29.51% and a negative return on equity of 10.90%. The firm's revenue was down 56.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.03 EPS.

Institutional Trading of OPKO Health

Large investors have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new stake in shares of OPKO Health in the 2nd quarter valued at approximately $27,000. Diversify Advisory Services LLC acquired a new position in OPKO Health in the second quarter valued at approximately $37,000. Abel Hall LLC purchased a new position in OPKO Health during the 1st quarter worth approximately $38,000. Partners Wealth Management LLC acquired a new stake in OPKO Health during the 3rd quarter worth approximately $43,000. Finally, EP Wealth Advisors LLC purchased a new position in OPKO Health in the second quarter worth $45,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health News Roundup

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722 million in cash, providing significant liquidity as the company shifts its focus toward biotech. OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
• Positive Sentiment: Q3 loss per share was reported at $0.05, better than the $0.07 loss analysts expected, offering a modest earnings bright spot. OPKO Health Reports Q3 Loss, Misses Revenue Estimates
• Neutral Sentiment: Following the Labcorp transaction, OPKO guided to $268 million–$278 million in 2026 revenue from continuing operations. This gives investors a post-sale benchmark, though it reflects a smaller business. OPKO sees FY 2026 continuing-ops revenue guidance
• Neutral Sentiment: Director John A. Paganelli sold a combined 13,601 shares in two reported transactions, while retaining roughly 389,914 shares. The sales were a small portion of his remaining stake. SEC ownership filing
• Negative Sentiment: Q3 revenue of $65.4 million was far below the $136.6 million FactSet estimate, weighing on the results. Investors also heard that biotech losses widened and the CAR-T program timeline was delayed. OPKO Health Q3 2026 Earnings Call Highlights

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.